Precision Hematology in Thalassemia: Integrating Multi-Omics, Artificial Intelligence, and Personalized Therapeutics
International Journal of Drug Delivery Technology · 17.06.2026 · 16 (56s)
DOI: 10.25258/ijddt.16.56s.3 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 17.06.2026. Verfasst von Avula Dhamini und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Thalassemia is among the most common monogenic hematological disorders worldwide and is characterized by defective globin-chain synthesis, ineffective erythropoiesis, chronic anemia, and systemic complications. Despite major advances in transfusion support and iron chelation therapy, considerable phenotypic heterogeneity persists among patients with similar genotypes, indicating the contribution of modifier genes, epigenetic regulation, and environmental factors. Precision hematology has emerged as a transformative approach that integrates multi-omics technologies, artificial intelligence (AI), and personalized therapeutics to enable individualized disease management. Genomics, transcriptomics, epigenomics, proteomics, metabolomics, and single-cell omics have collectively improved understanding of erythropoiesis, fetal hemoglobin regulation, oxidative stress, and iron homeostasis. Simultaneously, AIdriven computational models facilitate biomarker discovery, risk stratification, disease prediction, and optimization of therapeutic interventions. Recent advances in targeted pharmacological therapies, pharmacogenomics, gene addition therapy, and genome-editing technologies have further accelerated the transition toward precision medicine. Digital health technologies and predictive analytics are also enhancing longitudinal monitoring and clinical decision-making. This review summarizes the current landscape of precision hematology in thalassemia, emphasizing the integration of multi-omics, computational intelligence, and personalized therapeutics while discussing translational challenges and future opportunities for individualized and potentially curative care.
Zitieren
APA
Dhamini, A., Rathinam, T., & Rathinavelu, M. (2026). Precision Hematology in Thalassemia: Integrating Multi-Omics, Artificial Intelligence, and Personalized Therapeutics. International Journal of Drug Delivery Technology, 16(56s). https://doi.org/10.25258/ijddt.16.56s.3
Vancouver
Dhamini A, Rathinam T, Rathinavelu M. Precision Hematology in Thalassemia: Integrating Multi-Omics, Artificial Intelligence, and Personalized Therapeutics. International Journal of Drug Delivery Technology. 2026;16(56s). doi:10.25258/ijddt.16.56s.3
BibTeX
@article{Dhamini2026,
author = {Dhamini, Avula and Rathinam, Thirumalaikumaran and Rathinavelu, Mohanraj},
title = {Precision Hematology in Thalassemia: Integrating Multi-Omics, Artificial Intelligence, and Personalized Therapeutics},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {56s},
doi = {10.25258/ijddt.16.56s.3}
}
EUVIMED